The trusted source for information on cancer built in collaboration with millions of patients and the country's leading academic medical centers.
New York City
- Tweets 3,964
- Following 2,147
- Followers 2,774
- Likes 4,413
SurvivorNet retweeted
In a recent @SurvivorNetTeam feature, Dr. Akash Patnaik, MD, PhD, highlights growing momentum in precision-based targeted therapies, immune-based approaches, and radioligand treatments such as FPI-2265 for advanced prostate cancer. @AkashPatnaik7
ow.ly/vnZO50ZR6Yq
4
7
310
There’s power in hearing from someone who’s been there—SurvivorNet's #BreastCancer Dialogues franchise brings survivors together to talk openly about finding their confidence, navigating uncertainty, and making room for joy throughout the journey.
Here’s a look at those conversations: survivornet.com/series-the-b…
60
SurvivorNet retweeted
After decades of usage, the adequate calculation of carbo dosage remains controversial. One more reason to consider carboplatin-sparing approaches in HER2+ eBC, where recent data suggest marginal therapeutic role. Our thoughts out in @JCO_ASCO. @CucchiariD ascopubs.org/doi/10.1200/JCO…
1
20
66
5,789
SurvivorNet retweeted
The future of radiation oncology is on display at #ASTRO26. Moffitt is proud to be represented with more than 30 abstracts spanning breast, head and neck cancers, proton therapy, ctDNA and more.
Visit booth #2551 to meet our team and learn about the research that is redefining radiation oncology! #MoffittASTRO26
Explore our full presentation list:
bit.ly/3TjtgX7
2
7
19
3,918
Yes.. keep going.. patients need this better option…
We believe the promise of #CART isn't complete until it can reach the patients who need it – wherever they are. An excellent reminder that innovation and #patientaccess must move together. Read the full piece here: survivornet.com/articles/all… #celltherapy #oncology @SurvivorNetTeam
1
1
3
204
“My research is the work cited in LLMs, and there’s a huge amount relevant to patients that never makes it into the paper or the LLM.” Two of the country’s leading experts in #multiplemyeloma, Dr. @SagarLonialMD from @WinshipAtEmory and Dr. @VincentRK from @MayoCancerCare, argue that it’s essential to augment #AI with genuine medical expertise and empathy. We’re doing just that on SurvivorNet’s My Health Questions AI platform.
The video below is worth watching, and the product is worth checking out: survivornet.com/my-health-qu…
1
3
5
881
SurvivorNet retweeted
Still stuck on the rationale here. If it's to prevent resistance, that doesn't work, ESR1 comes up under AI pressure and this trial takes the AI out, so there's nothing to prevent. If it's to beat the AI head-on in 1L, that was always going to be hard, the disease is still estrogen-driven there and mostly ESR1-wildtype, so the SERD has nothing extra to do. So the question isn't why it missed. It's what they thought would make it win.
#bcsm
BREAKING: SERENA-4 is negative. Similar to giredestrant, camizestrant did not improve outcomes vs AI when combined to CDK4/6i in the 1L setting. Its role remains confined to pts with ESR1 mutations, which seems to be the sweet spot for oral SERDs in MBC. astrazeneca.com/media-centre…
3
3
21
3,583
SurvivorNet retweeted
WCLC 2026 is underway in Seoul with 7,500+ experts from 100+ countries.
We are reporting live on the studies most likely to reshape lung cancer care—from targeted therapies and ADCs to perioperative immunotherapy and AI-enabled early detection.
#WCLC26 #LungCancer
Made with AI
6
14
695
Every day in September, SurvivorNet is telling the stories of men and their families battling advanced prostate cancer. Today, we debuted a new show, Shoulder to Shoulder: Getting Through Prostate Cancer with @alroker. #PCAM
Check out the trailer and the link to see the full show: survivornet.com/shoulder-to-…
1
1
130
Have you tried MHQ: Clinical Intelligence? We think our My Health Questions AI for doctors is every bit as good as OpenEvidence, if not better. Why? It’s customized for #oncologists and clinical trial research. Try it out and let us know what you think.
snconnect.survivornet.com/mh…
2
127
This summer, we've hosted a series of events to help educate and enhance the understanding of the rapidly changing treatment paradigm across oncology. In the last 24 months, almost the entire non-muscle invasive bladder cancer treatment paradigm has shifted.
Drs. @MattGalsky (@IcahnMountSinai) and Alexandra Drakaki (@UCLAHealth) joined us to discuss these shifts, providing a clearer look at the decision-making around #ctDNA in bladder cancer, Immunotherapy response and toxicity management, and the #VOLGATrial.
These events are part of an invite-only series across oncology. If you're interested in joining future conversations, please get in touch at business@survivornet.com
1
3
91
SurvivorNet retweeted
A vaccine with ties to Siteman Cancer Center is showing great promise against melanoma. The mRNA-based therapy prevented the skin cancer from returning in high-risk patients in a global Phase III trial with 1,000+ patients.
1
5
9
635
SurvivorNet retweeted
The FDA approved a first-of-its-kind drug for aggressive prostate cancer. @WashUMedicine medical oncologist Russell Pachynski, MD, of Siteman tells @SurvivorNetTeam what it means for patients. survivornet.com/articles/the…
3
6
1,187
#CELMoD #ZENBEXUS is a first-of-its-kind approval in a new way of treating multiple myeloma. We had the chance to speak with one of the leaders in myeloma, @DanaFarber's Dr. Paul Richardson, about this groundbreaking treatment. This is an exciting part of how we’re educating patients and physicians.
snconnect.survivornet.com/ar…
128
SurvivorNet retweeted
Thanks @RahulBanerjeeMD for the outstanding editorial!! Readers will get more from it, than from the manuscript itself. All the key messages with balanced context.🙏🏼🙏🏼
New editorial by Swetha Reddi MD & @RahulBanerjeeMD discusses the recent article by Costa et al on redefining functional high-risk multiple myeloma in the era of QUAD + ASCT.
Editorial: acsjournals.onlinelibrary.wi…
Article: acsjournals.onlinelibrary.wi…
@End_myeloma @OncoAlert #MMSM
2
11
54
6,719
SurvivorNet retweeted
Dr. Peter O'Donnell is quoted in this @SurvivorNetTeam story about a newly approved bladder cancer treatment. survivornet.com/articles/new…
1
3
264
SurvivorNet retweeted
MyelomaRisk.com
One-stop free-to-use website to risk stratify myeloma, MGUS, smoldering myeloma, Waldenstroms Macroglobulinemia, Amyloidosis.
Also links to iStopMM calculator to determine when a bone marrow is needed in MGUS.
Will be regularly updated. More calculators and links to key articles will be added soon!
2
38
89
7,168
SurvivorNet retweeted
How long from protocol to paper? This one is 15 years.
RCTs especially IITs are hard work. @myelomaMD pulled it off through unbelievable hard work.
Just out!! In @NEJM - Our randomized trial in myeloma (ENDURANCE trial) shows limited duration of lenalidomide maintenance is just as good as indefinite therapy, with less side effects!!! @eaonc @theNCI
Implications are HUGE. This is a drug we spends billions on each year:
-Less side effects
-Less second cancers
-Similar overall survival
-Less cost
@myelomaMD @Myeloma_Doc @SagarLonialMD
National NCI funded trial led by @eaonc and joined by @ALLIANCE_org & @SWOG
nejm.org/doi/full/10.1056/NE…
5
31
167
34,348
SurvivorNet retweeted
FDA approved gedatolisib ((RPI3K/AKT/mTOR-PAM inhibition) + fulvestrant ± palbociclib for PIK3CA-WT HR+/HER2- mBC post-CDK4/6i. First PAM inhibitor to land in the WT space.
PFS- WT: triplet 9.3m, doublet 7.4m vs fulvestrant 2.0m (HR 0.24 / 0.33).
Two caveats. No head-to-head triplet vs doublet, each was benchmarked separately, so palbociclib's contribution is unproven. And a 2.0m control tells you how bad single-agent fulvestrant is post-CDK4/6i, not how this performs against what I'd actually reach for.
Cost: weekly IV, stomatitis 72% (22% G3), hyperglycemia, palbo neutropenia.
But the alternatives don't cover this patient. Elacestrant and vepdegestrant need ESR1. Capivasertib needs PIK3CA/AKT1/PTEN. In PIK3CA-WT/ESR1-WT the oral shelf is empty, and that's exactly where this is indicated.
Not a reflexive 2L default. Not dismissible either.
#gedatolisib #VIKTORIA1 #bcsm
Ref: Hurvitz SA, JCO 2026;44(12).
3
7
2,381
SurvivorNet retweeted
The @FDA approves gedatolisib as 2nd line therapy in combo with fulvestrant in tumors w/o PIK3CA mutations. Median PFS F, 2.0m, F+G, 7.4m, F+G+palbo 9.3m.
fda.gov/drugs/resources-info…
2
6
30
17,495